| ITN villages | Control villages | ITN Protective efficacy | |||||
---|---|---|---|---|---|---|---|---|
 | N | Pf episodes per 1,000 weeks exposure | N | Pf episodes per 1,000 weeks exposure | Rate ratio | Rate difference | ||
Dabhine | Â | Â | Â | Â | Â | Â | Â | Â |
Pair 1 | 677 | 4.04 | (97 /24034) | 715 | 15.25 | (376 /24662) | 0.26 | −11.21 |
Pair 2 | 522 | 7.37 | (137 /18592) | 653 | 3.51 | (83 /23625) | 2.09 | +3.86 |
Pair 3 | 429 | 1.57 | (24 /15304) | 280 | 9.38 | (91 /9697) | 0.17 | −7.81 |
Pair 4 | 208 | 2.83 | (21 /7411) | 171 | 8.03 | (48 /5980) | 0.35 | −5.20 |
Pair 5 | 67 | 2.13 | (5 /2343) | 71 | 13.32 | (33 /2477) | 0.16 | −11.19 |
Myothugyi | Â | Â | Â | Â | Â | Â | Â | Â |
Pair 6 | 74 | 3.68 | (9 /2447) | 44 | 3.84 | (6 /1562) | 0.96 | −0.16 |
Pair 7 | 737 | 0.23 | (6 /26632) | 786 | 0.46 | (13 /28427) | 0.50 | −0.23 |
Pair 8 | 482 | 0.06 | (1 /17344) | 595 | 0.97 | (21 /21637) | 0.06 | −0.91 |
Pair 9 | 653 | 1.61 | (37 /22973) | 631 | 0.57 | (13 /22852) | 2.82 | +1.04 |
Pair 10 | 140 | 2.90 | (14 /4824) | 107 | 7.68 | (29 /3775) | 0.38 | −4.78 |
Total | 3,989 | 2.47 | (351 /141903) | 4053 | 4.93 | (713 /144694) | weighted paired t-test p = 0.216 |